Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Inclusion Criteria: * Male or female, 18 to 75 years of age * Written informed consent * Body mass index (BMI) between 17.5 and 30.0 kg/m2 * No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment * No abnormal finding of clinical relevance * Diagnosis of HBeAg positive, immune active, chronic HBV infection * \> 2 months of continuous treatment with daily oral entecavir or tenofovir * Must use 2 effective methods of contraception (double barrier contraception or hormonal contraceptive along with a barrier contraceptive) Exclusion Criteria: * Pregnant or lactating * Acute signs of hepatitis/other infection within 4 weeks of screening * Hepatic transaminases (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]) \> 3 times the upper limits of normal * Liver Elastography (i.e. FibroScan®) score \> 9 * Antiviral therapy other than entecavir or tenofovir within 3 months of screening * Prior treatment with interferon in the last 3 years * Use of anticoagulants, corticosteroids, immunomodulators, or immunosuppressants within 6 months of screening * Use within 7 days prior to screening of dietary and/or herbal supplements that can interfere with liver metabolism * Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days of study drug administration * Use of prescription medication within 14 days prior to study drug administration * Depot injection/implant of any drug except birth control within 3 months prior to study drug administration * Known diagnosis of diabetes mellitus * History of autoimmune disease * Human immunodeficiency virus (HIV) infection * Sero-positive for Hepatitis C Virus (HCV), and/or a history of delta virus hepatitis * Hypertension; blood pressure \> 150/100 mmHg * History of cardiac rhythm disturbances * Family history of congenital long QT syndrome, Brugada syndrome or unexplained sudden cardiac death * Symptomatic heart failure, unstable angina, myocardial infarction, severe cardiovascular disease within 6 months prior to study entry * History of malignancy, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, in situ cervical cancer * Major surgery within 3 months of screening * History of alcohol and/or drug abuse \< 12 months from screening * Regular use of alcohol within 6 months (ie, more than 14 units of alcohol per week) * Evidence of systemic acute inflammation, sepsis, or hemolysis * Diagnosed with a significant psychiatric disorder * Use of drugs of abuse * History of allergy to bee venom * Positive reaction to the bee venom allergy immunoglobulin E (IgE) test * Use of investigational agents or devices within 30 days * Clinically significant inherited or acquired gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease * Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction * Clinically significant history or presence of uncontrolled systemic disease * Donated or had a loss of whole blood of 50 milliliters (mL) to 499 mL within 30 days or more than 499 mL between 31 and 56 days prior to study treatment * History of fever within 2 weeks of screening * Immunization/planned immunization with live attenuated vaccine except influenza vaccine * Presence of any medical or psychiatric condition or social situation that impacts compliance or results in additional safety risk * Excessive exercise/physical activity within 7 days of screening/enrolment or during study * History of coagulopathy/stroke within past 6 months, and/or concurrent anticoagulant medication(s)